Amgen targets physicians with biosimilars education campaign as 2023 shapes up as major shifting point

With 2023 poised to be a big year for biosimilars, Amgen is marketing to doctors to help them understand the biologic drugs — and get ready for patient questions. Why will people be asking more about biosimilars this year? The main reason is AbbVie’s megablockbuster Humira will get its first…

Click to view original post